‘Game-changing’ study finds diabetes drug a boon in HFpEF
The trial found the SGLT2 inhibitor empagliflozin was associated with a lower risk of hospitalisation for heart failure
Empagliflozin cuts the risk of hospitalisation from heart failure with preserved ejection fraction by almost 30% regardless of diabetes status, a major study shows.
Findings from the landmark EMPEROR-Preserved randomised placebo-controlled trial are of particular importance given the narrow range of treatments available for this patient cohort, the researchers say.
